Featured Trial
Clinical Trial Goal
To find out if zedenoleucel is safe and works well to treat AML
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML and 1 of the following:
- Are planning to have an allogeneic (cells from a donor) blood or marrow transplant (BMT) or
- The AML has come back (relapse or minimal residual disease) after having an allogeneic BMT
- Have not had more than 1 allogeneic BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Zedenoleucel is made from T cells (a type of immune cell) from the same donor used for the BMT. Doctors think that T cells treated in a lab to become tumor-associated antigen (TAA)-specific T cells may help your body to find and destroy leukemia cells.
For individuals who have not yet had an allogeneic BMT, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in.
- Group 1 – Zedenoleucel
- Group 2 – Standard treatment
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
If you're in Group 1, you'll get zedenoleucel, given as an intravenous (IV) infusion about 3 months after allogeneic BMT or when the clinical trial doctors think it's best for your health.
If you're in Group 2, you'll get standard treatment after allogeneic BMT. If the AML relapses or MRD is detected, you can go into Group 1.
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has not yet approved zedenoleucel.
Contacts
Gerald Garrett, 713.400.6400, ggarrett@markertherapeutics.com
Mythilli Koneru, MD, PhD, 713.400.6400, mkoneru@markertherapeutics.com
Locations
Sponsors
lead: Marker Therapeutics, Inc.
